1. Search Result
Search Result
Results for "

myocardial function

" in MedChemExpress (MCE) Product Catalog:

34

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

6

Peptides

7

Natural
Products

2

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1409

    ISDN

    NO Synthase Cardiovascular Disease
    Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI) .
    Isosorbide dinitrate
  • HY-P0125
    Elamipretide
    Maximum Cited Publications
    15 Publications Verification

    MTP-131; RX-31; SS-31

    Mitochondrial Metabolism Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Elamipretide (MTP-131) is a mitochondria-targeting peptide, which ameliorates myocardial infarction, improves the renal function and protects neurons form inflammatory and oxidative stress injury .
    Elamipretide
  • HY-106045

    CI 914 free base

    Phosphodiesterase (PDE) Cardiovascular Disease
    Imazodan is a selective inhibitor for phosphodiesterase III (PDE III), which increases myocardial contractility by blocking the cAMP degradation, and improves the contractile function of heart. Imazodan serves also as a peripheral vasodilator .
    Imazodan
  • HY-106844A

    Others Cardiovascular Disease
    (+)-EMD 57033 is a cardiac troponin C (cTnC) activator, is a dominant Ca 2+ sensitizer. (+)-EMD 57033 binds the cardiac/slow skeletal troponin C isoform and exerts myocardial contractile promotion function .
    (+)-EMD 57033
  • HY-176716

    Aldehyde Dehydrogenase (ALDH) Cardiovascular Disease
    ALDH2 activator 1 (Compound Z17) is an allosteric aldehyde dehydrogenase 2 (ALDH2) agonist. ALDH2 activator 1 enhances cardiac function and reduces myocardial necrosis in a mouse model of myocardial ischemia-reperfusion. ALDH2 activator 1 is promising for research of cardiovascular diseases such as myocardial infarction (MI) .
    ALDH2 activator 1
  • HY-121259

    Adriamycinol; DXR-OL

    Endogenous Metabolite Cardiovascular Disease
    Doxorubicinol, a potent inhibitor of the cardiac sarcoplasmic reticulum calcium pump, inhibits systolic myocardial function in isolated heart muscle. Doxorubicinol inhibits tumor cell growth and has cardiotoxicity.
    Doxorubicinol
  • HY-176347S

    Isotope-Labeled Compounds Cancer
    Alpha Feto Protein, Arg- 13C36, 15N4, Lys- 13C6, 15N2 is the 13C- and 15N-labeled Alpha Feto Protein.
    Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2
  • HY-123721

    AWD-19-166; GS 015

    Endogenous Metabolite Cardiovascular Disease
    Tiracizine hydrochloride (AWD-19-166) is a Class I antiarrhythmic drug with activity that reduces myocardial contractile function. Tiracizine hydrochloride was studied in patients with ischemic heart disease, showing its effects on the myocardium. Tiracizine hydrochloride reduces myocardial contractility and may have potential use in the management of heart disease .
    Tiracizine hydrochloride
  • HY-B1409S

    ISDN-13C6

    NO Synthase Cardiovascular Disease
    Isosorbide dinitrate- 13C6 is the 13C labeled Isosorbide dinitrate . Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI) .
    Isosorbide dinitrate-13C6
  • HY-B1409R

    ISDN (Standard)

    Reference Standards NO Synthase Cardiovascular Disease
    Isosorbide dinitrate (Standard) is the analytical standard of Isosorbide dinitrate. This product is intended for research and analytical applications. Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI) .
    Isosorbide dinitrate (Standard)
  • HY-112205
    RR-11a
    2 Publications Verification

    Legumain Cancer
    RR-11a is a synthetic enzyme inhibitor of Legumain (IC50=31-55 nM). RR-11a can be used for the research of cancer and acute myocardial infarction (AMI) .
    RR-11a
  • HY-106045A

    CI 914

    Phosphodiesterase (PDE) Cardiovascular Disease
    Imazodan hydrochloride is the hydrochloride form of Imazodan (HY-106045). Imazodan hydrochloride is a selective inhibitor for phosphodiesterase III (PDE III), which increases myocardial contractility by blocking the cAMP degradation, and improves the contractile function of heart. Imazodan hydrochloride serves also as a peripheral vasodilator .
    Imazodan hydrochloride
  • HY-W803860

    Drug Metabolite Sodium Channel Cardiovascular Disease
    N-Depropylpropafenone is an active metabolite of Propafenone (HY-B0432), generated through the CYP450 enzyme system (mainly CYP2D6). It functions by blocking sodium ion channels, slowing myocardial conduction and exhibiting certain antiarrhythmic effects .
    N-Depropylpropafenone
  • HY-174673

    mRNA Cancer
    Human GATA4 mRNA encodes the human GATA binding protein 4 (GATA4) protein, a member of the GATA family of zinc-finger transcription factors. GATA4 is thought to regulate genes involved in embryogenesis and in myocardial differentiation and function. It is also necessary for normal testicular development.
    Human GATA4 mRNA
  • HY-N6020B

    Others Cardiovascular Disease Inflammation/Immunology
    Butin is a major biologically active flavonoid isolated from the heartwood of Dalbergia odorifera with oral activity, with strong antioxidant, antiplatelet and anti-inflammatory activities. Butin significantly alleviates myocardial infarction and improves heart function, together with prevents diabetes-induced cardiac oxidative damage in rat .
    Butin
  • HY-N6020BR

    Others Cardiovascular Disease Inflammation/Immunology
    Butin is a major biologically active flavonoid isolated from the heartwood of Dalbergia odorifera with oral activity, with strong antioxidant, antiplatelet and anti-inflammatory activities. Butin significantly alleviates myocardial infarction and improves heart function, together with prevents diabetes-induced cardiac oxidative damage in rat .
    Butin (Standard)
  • HY-121705

    Endogenous Metabolite Apoptosis Bcl-2 Family NF-κB Survivin Src Akt AMPK NO Synthase Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Propionyl-L-carnitine is an orally active L-carnitine derivative. Propionyl-L-carnitine has a high affinity for muscle L-carnitine transferase. Propionyl-L-carnitine increases Apoptosis, Bax, and reduces NF-κB, VCAM-1, MCP-1, and survivin. Propionyl-L-carnitine activates Src kinase, Akt, induces p-AMPK and nitric oxide synthesis. Propionyl-L-carnitine alleviates cardiovascular disease, obesity, and colitis .
    Propionyl-L-carnitine
  • HY-P0125B
    Elamipretide triacetate
    Maximum Cited Publications
    15 Publications Verification

    MTP-131 triacetate; RX-31 triacetate; SS-31 triacetate

    Mitochondrial Metabolism Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Elamipretide triacetate (MTP-131 triacetate; RX-31 triacetate; SS-31 triacetate) is Elamipretide triacetate form of Elamipretide (HY-P0125). Elamipretide triacetate is a mitochondria-targeting peptide, which ameliorates myocardial infarction, improves the renal function and protects neurons form inflammatory and oxidative stress injury .
    Elamipretide triacetate
  • HY-P0125A

    MTP-131 TFA; RX-31 TFA; SS-31 TFA

    Mitochondrial Metabolism Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Elamipretide TFA (MTP-131 TFA; RX-31 TFA; SS-31 TFA) is the TFA salt form of Elamipretide (HY-P0125). Elamipretide TFA is a mitochondria-targeting peptide, which ameliorates myocardial infarction, improves the renal function and protects neurons form inflammatory and oxidative stress injury .
    Elamipretide TFA
  • HY-101415

    Ubiquinone Q9; CoQ9; Ubiquinone 9

    Apoptosis Endogenous Metabolite Cardiovascular Disease
    Coenzyme Q9 (Ubiquinone Q9), the major form of ubiquinone in rodents, is an amphipathic molecular component of the electron transport chain that functions as an endogenous antioxidant. Coenzyme Q9 attenuates the diabetes-induced decreases in antioxidant defense mechanisms. Coenzyme Q9 improves left ventricular performance and reduces myocardial infarct size and cardiomyocyte apoptosis .
    Coenzyme Q9
  • HY-18100A
    PRE-084 hydrochloride
    10+ Cited Publications

    Sigma Receptor Akt NO Synthase Cardiovascular Disease Neurological Disease
    PRE-084 hydrochloride is a highly selective σ1 receptor (S1R) agonist, with an IC50 of 44 nM. PRE-084 hydrochloride exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 hydrochloride also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway .
    PRE-084 hydrochloride
  • HY-18100

    Sigma Receptor Akt NO Synthase Cardiovascular Disease Neurological Disease
    PRE-084 is a highly selective σ1 receptor (S1R) agonist, with an IC50 of 44 nM. PRE-084 exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway .
    PRE-084
  • HY-121586

    Bay g 6575

    Lipoxygenase Cardiovascular Disease
    Nafazatrom (Bay g 6575) is an orally active cardioprotective agent that protects against ischemic damage. Nafazatrom dose-dependently inhibits neutrophil aggregation, superoxide anion generation, arachidonic acid metabolism, and to a lesser extent the release of β-glucosidase, platelet aggregation or arachidonic acid in vitro. Acid metabolism has no significant effect. In a dog ischemia-reperfusion model, Nafazatrom (10 mg/kg; po) reduced infarct size and the occurrence of arrhythmias and rescued ischemic myocardial function without affecting any hemodynamic changes. The basis of Nafazatrom's cardioprotection may be inhibition of neutrophil function and cellular infiltration in vitro .
    Nafazatrom
  • HY-P3304

    GHSR Neurological Disease Cancer
    MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer .
    MR 409
  • HY-173572

    Sirtuin Autophagy Cardiovascular Disease
    SKLB-11A is a selective, orally active and allosteric SIRT3 (sirtuin 3) agonist with a Kd value of 4.7 μM. SKLB-11A is highly selective for other members of the SIRT family. SKLB-11A activates autophagy-related signaling pathways, prevents mitochondrial dysfunction, improves cardiac function in Doxorubicin (HY-15142A)-induced cardiotoxicity and myocardial ischemia/reperfusion models .
    SKLB-11A
  • HY-101415R

    Ubiquinone Q9 (Standard); CoQ9 (Standard); Ubiquinone 9 (Standard)

    Reference Standards Apoptosis Endogenous Metabolite Cardiovascular Disease
    Coenzyme Q9 (Standard) is the analytical standard of Coenzyme Q9. This product is intended for research and analytical applications. Coenzyme Q9 (Ubiquinone Q9), the major form of ubiquinone in rodents, is an amphipathic molecular component of the electron transport chain that functions as an endogenous antioxidant. Coenzyme Q9 attenuates the diabetes-induced decreases in antioxidant defense mechanisms. Coenzyme Q9 improves left ventricular performance and reduces myocardial infarct size and cardiomyocyte apoptosis .
    Coenzyme Q9 (Standard)
  • HY-101390B

    Calcium Channel Cardiovascular Disease
    Niguldipine free base is a calcium channel blocker with activity in regulating cardiovascular function. Niguldipine free base can reduce systolic and diastolic blood pressure, thereby increasing heart rate and cardiac output. Niguldipine free base exhibits dose-dependent and sustained increases in coronary blood flow. Niguldipine free base also increases perfusion in the kidneys and femoral arteries, but the effect is temporary and to a lesser extent. The effect of Niguldipine free base on myocardial metabolism is not significant .
    Niguldipine free base
  • HY-P10336

    Serpin Neurological Disease Endocrinology
    Serpinin is an agonist of the protease inhibitor Nexin-1 (PN-1). Serpinin upregulates the expression of PN-1 through the cAMP-PKA-Sp1 signaling pathway, promoting granule biogenesis in endocrine cells. Serpinin is used in research related to the regulation of secretory function . Serpinin is a selective agonist for β-adrenergic receptors. Serpinin interacts with β1-adrenergic receptors to activate the AC-cAMP-PKA pathway, which regulates myocardial systolic and diastolic function. pGlu-serpinin upregulates Bcl2 mRNA transcription and exerts neuroprotective effects .
    Serpinin
  • HY-18100AR

    Reference Standards Sigma Receptor Akt NO Synthase Cardiovascular Disease Neurological Disease
    PRE-084 (hydrochloride) (Standard) is the analytical standard of PRE-084 (hydrochloride). This product is intended for research and analytical applications. PRE-084 hydrochloride is a highly selective σ1 receptor (S1R) agonist, with an IC50 of 44 nM. PRE-084 hydrochloride exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 hydrochloride also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway .
    PRE-084 hydrochloride (Standard)
  • HY-129763

    Fluorescent Dye Cardiovascular Disease
    Di-4-ANEPPS is a voltage-sensitive dye that acts on voltage-gated ion channels (such as sodium channels) and inhibits sodium current, significantly reducing sodium current density, although specific values like IC50 remain unclear. It mainly binds to the voltage-sensitive regions on the cell membrane, changing its fluorescence properties to reflect membrane potential changes and thus affecting the function of ion channels to exert its activity. This substance can be used in cardiovascular research, such as the electrophysiology of cardiomyocytes, myocardial ischemia, and the effects of drugs on cardiomyocytes. It is of great value in evaluating drug cardiotoxicity and exploring the mechanisms of arrhythmias .
    Di-4-ANEPPS
  • HY-19867A
    Burixafor hydrobromide
    2 Publications Verification

    TG-0054 hydrobromide

    CXCR VEGFR Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Burixafor (TG-0054) hydrobromide is a selective, orally active CXCR4 antagonist that effectively blocks the interaction between CXCR4 and its ligand, stromal cell-derived factor SDF-1. Burixafor hydrobromide interferes with the SDF-1/CXCR4 signaling pathway, prompting the release of bone marrow stem cells into the peripheral circulation, exerting immunomodulatory and anti-inflammatory activities. Burixafor hydrobromide can be used in the study of cancer, Intraocular neovascular diseases (such as choroidal neovascularization), myocardial infarction and other diseases, with the potential to mobilize stem cells, improve cardiac function and reduce inflammatory responses .
    Burixafor hydrobromide
  • HY-174400

    SGLT SOD Na+/H+ Exchanger (NHE) Autophagy Cardiovascular Disease
    SGLT2-IN-2 (Compound E9) is an inhibitor of SGLT2. SGLT2-IN-2 significantly enhances the inhibition of SGLT2, NHE1, and SOD enzyme activity. SGLT2-IN-2 has protective effect on the glucose-free DMEM-induced injured cardiomyocytes. SGLT2-IN-2 significantly improves cardiac function in TAC-induced HF mice and inhibits cardiomyocyte hypertrophy as well as collagen deposition. SGLT2-IN-2 can ameliorate myocardial tissue damage and enhance mitochondrial autophagy in injured cardiomyocytes, thereby increasing survival rates in HF mice .
    SGLT2-IN-2
  • HY-158426
    2-APQC
    1 Publications Verification

    Sirtuin Cardiovascular Disease
    2-APQC is an orally active and selective agonist of Sirtuin-3 (SIRT3) (Kd=2.756 μM), antagonizes Isoproterenol/ISO (HY-B0468)-induced cytotoxicity. 2-APQC activates the SIRT3-PYCR1 axis to enhance mitochondrial proline metabolism and inhibit the ROS-p38MAPK pathway by inhibiting signaling pathways such as mTOR-p70S6K, JNK, and TGF-β/Smad3. 2-APQC also activates the AMPK-Parkin axis to alleviate myocardial hypertrophy and fibrosis and protect cardiac function. 2-APQC can be used in the study of heart failure .
    2-APQC
  • HY-N6850
    Calenduloside E
    1 Publications Verification

    Apoptosis Pyroptosis AMPK Bcl-2 Family JAK STAT Calcium Channel Interleukin Related TNF Receptor SOD Reactive Oxygen Species (ROS) PPAR Cardiovascular Disease Inflammation/Immunology
    Calenduloside E is a pentacyclic triterpenoid saponin that can be extracted from the bark and roots of Aralia ovata, and has anti-inflammatory and anti-apoptotic activities. Calenduloside E alleviates atherosclerosis by regulating macrophage polarization, improves mitochondrial function by regulating the AMPK-SIRT3 pathway, and alleviates acute liver injury. In addition, Calenduloside E promotes the interaction between L-type calcium channels and Bcl-2 related apoptosis genes, inhibits calcium overload, and alleviates myocardial ischemia/reperfusion injury. Calenduloside E also improves non-alcoholic fatty liver disease by regulating heat shock-dependent pathways, and inhibits ROS mediated JAK1-STAT3 pathways to reduce cellular inflammatory responses .
    Calenduloside E

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: